首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2048054

左旋多巴市場－全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局分類，2021-2031年

Levodopa Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球左旋多巴市場預計將從 2025 年的 1.8101 億美元成長到 2031 年的 2.4845 億美元，複合年成長率為 5.42%。

左旋多巴是多巴胺的代謝前體，是治療帕金森氏症運動症狀的主要治療方法。全球人口老化、需要持續多巴胺替代治療的神經退化性疾病盛行率不斷上升，以及發展中國家診斷能力的提高（使得先前未被診斷的患者群體得以被發現），都推動了左旋多巴市場的發展。然而，主要品牌製劑專利到期加劇了學名藥的競爭，限制了老牌製藥公司的收入成長潛力。同時，預計到2025年，帕金森氏症每年對美國造成的經濟負擔將達到約615億美元，凸顯了全球對左旋多巴製劑的持續依賴。

市場概覽
預測期	2027-2031
市場規模：2025年	181,010,000 美元
市場規模：2031年	2.4845億美元
複合年成長率：2026-2031年	5.42%
成長最快的細分市場	直接的
最大的市場	北美洲

市場促進因素

人口快速老化是全球左旋多巴市場的主要促進因素，因為年齡是帕金森氏症的主要風險因素。隨著全球平均壽命的延長，尤其是在已開發國家，需要多巴胺替代療法的患者人數也相應增加，這促使標準療法的生產量不斷成長。在美國，每年約有9萬人被診斷出罹患帕金森氏症。同時，緩釋製劑和聯合治療的出現正在重塑市場格局，這些製劑和療法旨在減輕傳統口服左旋多巴引起的運動功能波動。製藥公司正積極投資新的給藥系統，例如先進的膠囊技術和持續皮下輸注，以穩定血漿藥物濃度並提高患者的遵守用藥。這些創新技術能夠更好地控制症狀，並允許更高的定價，從而有效減少因學名藥競爭造成的收入損失。一種緩釋配方預計每天可增加 0.5 小時的“有效作用時間”，並產生超過 2.5 億美元的年淨銷售額。

市場挑戰

主要品牌左旋多巴製劑專利到期對全球市場的財務估值構成重大障礙。一旦壟斷期結束，非專利生產商的進入將帶來成本效益高、生物等效的替代產品，從而擾亂現有製藥公司的定價策略。非專利藥的飽和迫使整個市場降價，使該行業從高利潤行業轉變為以大眾市場主導、盈利顯著下降的行業，導致原研藥公司收益迅速下滑。儘管臨床需求不斷成長，但這種價格壓力仍然十分嚴峻。例如，預計到2025年，美國將新增約9萬例帕金森氏症病例，顯示患者數量正在增加。然而，價格具有競爭力的非專利的廣泛供應已顯著抑制了整體市場成長，限制了從需求成長中獲得的經濟效益。

市場趨勢

吸入式左旋多巴粉劑的商業化正在為間歇性運動障礙的急性治療開闢一個重要的細分市場，尤其針對那些儘管接受標準維持治療仍持續存在的「關期」症狀。與口服維持療法不同，這些肺部給藥系統能夠快速被全身吸收，在運動症狀意外復發時提供即時緩解。這個急救治療領域正在經歷顯著的整合和企業價值的提升，例如默茲治療公司（Merz Therapeutics）以1.85億美元收購了Inbrija品牌。同時，採用智慧給藥裝置的微片製劑正成為一種明顯的趨勢，它能夠為進行進行性帕金森氏症患者提供個人化的給藥方案。這種方法克服了固定劑量固態口服製劑的局限性，透過允許臨床醫生以微量單位調整左旋多巴的劑量，最佳化了治療窗口，並最大限度地降低了峰值劑量運動障礙的風險。這些高精度給藥系統和數位監測工具的整合正在推動歐洲及其他地區專業製藥公司的業務擴張。這也體現在 Navamedic 強勁的季度銷售額上，部分原因是其在歐洲擴大了微片製劑的銷售權。

The Global Levodopa Market is projected to grow from USD 181.01 Million in 2025 to USD 248.45 Million by 2031, achieving a 5.42% CAGR. As a metabolic precursor to dopamine, Levodopa serves as the primary pharmacological treatment for motor symptoms in Parkinson's disease. Market expansion is driven by the aging global population and the increasing incidence of neurodegenerative conditions requiring consistent dopaminergic replacement, further supported by enhanced diagnostic capabilities in developing regions that identify previously undiagnosed patient pools. However, patent expirations for key branded formulations are intensifying generic competition, thereby constraining revenue potential for established pharmaceutical entities, despite the substantial annual economic burden of Parkinson's disease, estimated at nearly $61.5 billion in the United States by 2025, which underscores the sustained global reliance on levodopa therapeutics.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 181.01 Million
Market Size 2031	USD 248.45 Million
CAGR 2026-2031	5.42%
Fastest Growing Segment	Direct
Largest Market	North America

Market Driver

The rapid expansion of the geriatric population serves as the primary catalyst for the global levodopa market, given that advanced age is the leading risk factor for Parkinson's disease. As global life expectancy rises, particularly in developed nations, the patient pool requiring dopaminergic replacement therapy scales proportionally, necessitating higher production volumes of standard-of-care medications, with approximately 90,000 people diagnosed annually in the US. Concurrently, the market is being reshaped by the development of extended-release and combination therapies designed to mitigate motor fluctuations associated with traditional oral levodopa. Pharmaceutical companies are aggressively investing in novel delivery systems, such as advanced capsule technologies and continuous subcutaneous infusions, to ensure stable plasma drug concentrations and improve patient adherence. These innovations offer superior symptom control and command premium pricing, effectively countering revenue erosion from generic competition, with one extended-release formulation showing a 0.5-hour increase in daily 'Good On' time and projecting peak annual net sales over $250 million.

Market Challenge

The expiration of patents for key branded levodopa formulations poses a significant impediment to the global market's financial valuation. As exclusivity periods conclude, the entry of generic manufacturers introduces cost-effective bioequivalent alternatives, disrupting the pricing strategies of established pharmaceutical entities. This saturation of generic options forces a market-wide reduction in drug prices, shifting the sector from a high-margin business to one driven by high volume with significantly reduced profitability, causing rapid revenue erosion for originator companies. This pricing pressure is particularly acute despite rising clinical demand; for instance, approximately 90,000 individuals in the United States were newly diagnosed with Parkinson's disease in 2025, indicating a growing patient pool. However, the market's overall monetary expansion is severely curtailed by the widespread adoption of competitively priced generic formulations, limiting economic capitalization on increasing demand.

Market Trends

The commercialization of inhalable levodopa powders is establishing a critical niche for the acute management of intermittent motor fluctuations, specifically targeting 'off' episodes that persist despite standard maintenance therapy. These pulmonary delivery systems provide rapid systemic absorption for immediate relief when motor symptoms unexpectedly re-emerge, distinct from oral maintenance regimens. This rescue therapy segment is experiencing significant consolidation and valuation, exemplified by Merz Therapeutics' $185 million acquisition of the Inbrija franchise. Concurrently, a definitive shift is observed towards microtablet formulations that utilize smart dispensing devices to facilitate personalized dosing regimes for patients with advanced Parkinson's disease. This approach addresses the limitations of fixed-dose solid oral dosage forms by allowing clinicians to titrate levodopa in minute increments, thereby optimizing the therapeutic window and minimizing the risk of peak-dose dyskinesia. The integration of these high-precision delivery systems with digital monitoring tools is driving commercial expansion for specialized pharmaceutical providers in Europe and beyond, as seen in Navamedic's strong quarterly revenues, partly driven by its expanded European commercial rights for microtablet solutions.

Key Market Players

Shandong Xinhua Pharmaceutical Co., Ltd.
Wild Wind Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Yefeng Pharmaceutical Co., Ltd
SHADRI LAB PRIVATE LTD
Divi's Laboratories Limited
Zhejiang Zhenyuan Co., Ltd.
EMBIO LIMITED
J.K. LIFECARE CENTERS PVT. LTD
Hetero Drugs Limited

Report Scope

In this report, the Global Levodopa Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Levodopa Market, By Sales Channel

Direct
Indirect

Levodopa Market, By End Use

Parkinson's Disease
Restless Legs Syndrome
Dyskinesia Management
Alzheimer's Disease
Others

Levodopa Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Levodopa Market.

Available Customizations:

Global Levodopa Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Levodopa Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Sales Channel (Direct, Indirect)
- 5.2.2. By End Use (Parkinson's Disease, Restless Legs Syndrome, Dyskinesia Management, Alzheimer's Disease, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Levodopa Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Sales Channel
- 6.2.2. By End Use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Levodopa Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Sales Channel
    - 6.3.1.2.2. By End Use
- 6.3.2. Canada Levodopa Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Sales Channel
    - 6.3.2.2.2. By End Use
- 6.3.3. Mexico Levodopa Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Sales Channel
    - 6.3.3.2.2. By End Use

7. Europe Levodopa Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Sales Channel
- 7.2.2. By End Use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Levodopa Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Sales Channel
    - 7.3.1.2.2. By End Use
- 7.3.2. France Levodopa Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Sales Channel
    - 7.3.2.2.2. By End Use
- 7.3.3. United Kingdom Levodopa Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Sales Channel
    - 7.3.3.2.2. By End Use
- 7.3.4. Italy Levodopa Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Sales Channel
    - 7.3.4.2.2. By End Use
- 7.3.5. Spain Levodopa Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Sales Channel
    - 7.3.5.2.2. By End Use

8. Asia Pacific Levodopa Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Sales Channel
- 8.2.2. By End Use
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Levodopa Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Sales Channel
    - 8.3.1.2.2. By End Use
- 8.3.2. India Levodopa Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Sales Channel
    - 8.3.2.2.2. By End Use
- 8.3.3. Japan Levodopa Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Sales Channel
    - 8.3.3.2.2. By End Use
- 8.3.4. South Korea Levodopa Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Sales Channel
    - 8.3.4.2.2. By End Use
- 8.3.5. Australia Levodopa Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Sales Channel
    - 8.3.5.2.2. By End Use

9. Middle East & Africa Levodopa Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Sales Channel
- 9.2.2. By End Use
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Levodopa Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Sales Channel
    - 9.3.1.2.2. By End Use
- 9.3.2. UAE Levodopa Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Sales Channel
    - 9.3.2.2.2. By End Use
- 9.3.3. South Africa Levodopa Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Sales Channel
    - 9.3.3.2.2. By End Use

10. South America Levodopa Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Sales Channel
- 10.2.2. By End Use
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Levodopa Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Sales Channel
    - 10.3.1.2.2. By End Use
- 10.3.2. Colombia Levodopa Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Sales Channel
    - 10.3.2.2.2. By End Use
- 10.3.3. Argentina Levodopa Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Sales Channel
    - 10.3.3.2.2. By End Use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Levodopa Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Shandong Xinhua Pharmaceutical Co., Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Wild Wind Pharmaceutical
15.3. Zhejiang Huahai Pharmaceutical
15.4. Zhejiang Yefeng Pharmaceutical Co., Ltd
15.5. SHADRI LAB PRIVATE LTD
15.6. Divi's Laboratories Limited
15.7. Zhejiang Zhenyuan Co., Ltd.
15.8. EMBIO LIMITED
15.9. J.K. LIFECARE CENTERS PVT. LTD
15.10. Hetero Drugs Limited